Therma Bright Inc.

Therma Bright Announces 1st Tranche Financing for $550,000 Through an Equity Private Placement and Convertible Debenture Offering

Therma Bright Announces: Further Testing of TherOZap(TM) Technology at Inhibiting Zika and Other Mosquito Borne Diseases, Proposed Financings and Acquisition Update

Therma Bright to Amend Definitive Agreement to Acquire ClearTouch(R) Nail Phototherapy Device and no!no! skin(R) Phototherapy Acne Device

Therma Bright Signs Definitive Agreement to Acquire ClearTouch(R) Nail Phototherapy Device and no!no! skin(R) Phototherapy Acne Device

Therma Bright Finalizes Terms on Acquisition, Adds Advisory Board Member and Grants Options

Jenex Announces Continuation to BC and Name Change to ‘Therma Bright Inc.’

Jenex Announces Non-Binding Letter of Intent with Quinsam Capital Corp. for $250,000 Investment to Develop CBD and THC Related Thermal Therapy Technology for Pain Relief and Other Pain Related Applications

Jenex Completes Due Diligence on Acquisition Targets

The Jenex Corporation Announces Board Change; Appointment of Advisory Board, Debt Settlement and Option Grants

Jenex’s TherOZap(TM) Technology Indicates Effectiveness in Inhibiting Zika Virus After Pre-Clinical Study

The Jenex Corporation Announces Graduation to the TSX Venture, Update on Chinese Global Financial Forum and Proposed Acquisition

The Jenex Corporation Announces Completion of Debt Settlement, Files TherOZap(TM) Device Patent and Presents at Chinese Global Financial Forum

The Jenex Corporation Announces AGM Results and Submits Application to Graduate to TSXV

The Jenex Corporation Signs Letter of Intent to Acquire Medical Device Assets

The Jenex Corporation Reports Promising Initial Results on Zika Virus Testing with TherOZap(TM)

The Jenex Corporation Announces Approvals of Equity Financing & Move to TSX Venture Exchange (TSXV)

Jenex Reports Expected Date of Test Results for TherOZap(TM) at Inactivating the Zika Virus

The Jenex Corporation Announces Conditional Acceptance of Reactivation from NEX to TSX Venture Exchange, TherOZap(TM) Testing and ISO 13485:2003 Update

The Jenex Corporation Completes $317,500 Oversubscribed Non-Brokered Private Placement with Insider Participation

Jenex Finalizing Protocol to Test TherOZap(TM) Against the Zika Virus with University Health Network

Jenex to Test TherOZap(TM) Working Prototype and Topical Cannabidiol Oil Against the Zika and West Nile Viruses

Jenex Completes Design of TherOZap(TM) Working Prototype and Signs Service Agreement with University Heath Network to initiate testing against the Zika and West Nile Viruses

Jenex Provides Update on TherOZap(TM) Working Prototype, and InterceptCS

Jenex to Test Next Generation Technology, TherOZap(TM) Against the Zika Virus and West Nile Virus